IL9 and myeloid sarcoma: Accordingly, levels of IL-9 in the cerebrospinal fluid (CSF) of relapsing-remitting (RR) MS patients were shown to inversely correlate with indexes of inflammation, neurodegeneration, disability progression, and response to first line therapies [12].